Skip to content
2000
Volume 21, Issue 32
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Synthetic nucleoside or nucleotide analogues played a key role to the development of antiviral agents in past decades. However, low membrane permeability and insufficient cellular phosphorylation impaired the biological activity of polar nucleoside drugs because they have to penetrate the cell membrane and be phosphorylated to active metabolite stepwise by intracellular enzymes. To overcome these limitations, diverse lipophilic prodrug modifications based on nucleoside mono-, di-, and triphosphate were designed and put into practice to efficiently deliver nucleoside into the target site, and bypass the rate-limited phosphorylation step. As the most successful prodrug strategy, ProTide technology has led to the discovery of three FDA-approved antiviral agents, including sofosbuvir, tenofovir alafenadmide, and remdesivir, which has been authorized for emergency use in patients of COVID-19 in the US. In recent years, nucleoside di- and triphosphate prodrugs have also made the significant progress. This review will focus on the summary of design approach and metabolic activation path of different nucleotide prodrug strategies. The potential application of nucleotide prodrugs for the treatment of COVID-19 was also described due to the pandemic of SARS-CoV-2.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026621666210728094019
2021-12-01
2025-07-04
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026621666210728094019
Loading

  • Article Type:
    Review Article
Keyword(s): Antiviral; Metabolic activation; Nucleoside; Nucleotide prodrug; Phosphorylation; ProTide
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test